RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30163% above fair value

$1.16−0.06 (-4.92%)

Close on Nov 12, 2026Market cap $52.35MP/E –Yield –

RenovoRx operating margin

Operating margin is operating income as a percentage of revenue.

RenovoRx's operating margin for the twelve months ending Sep 30, 2026 was -489.0%. For fiscal 2025 it was -1114.0%, against -25511.6% the year before.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-1114.0%	+24397.6
FY2024	Dec 31, 2024	-25511.6%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-303.6%	+899.4
Q2 FY2026	Jun 30, 2026	-368.4%	+266.2
Q1 FY2026	Mar 31, 2026	-616.2%	+962.5
Q4 FY2025	Dec 31, 2025	-1479.8%	–
Q3 FY2025	Sep 30, 2025	-1203.0%	–
Q2 FY2025	Jun 30, 2025	-634.6%	–
Q1 FY2025	Mar 31, 2025	-1578.7%	–